Last reviewed · How we verify
ST266 delayed — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
ST266 delayed (ST266 delayed) — Noveome Biotherapeutics, formerly Stemnion.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ST266 delayed TARGET | ST266 delayed | Noveome Biotherapeutics, formerly Stemnion | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ST266 delayed CI watch — RSS
- ST266 delayed CI watch — Atom
- ST266 delayed CI watch — JSON
- ST266 delayed alone — RSS
Cite this brief
Drug Landscape (2026). ST266 delayed — Competitive Intelligence Brief. https://druglandscape.com/ci/st266-delayed. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab